Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)

Scynexis' (SCYX) quarterly Cash from Financing Activities came in at $13.5 million in Q2 2026, down 44.01% quarter-over-quarter from $24.0 million in Q1 2026.

Analysis

Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Cash from Financing Activities for 14 consecutive years, with $13.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Financing Activities changed N/A year-over-year to $13.5 million; the trailing twelve-month figure through Jun 2026 stood at $37.4 million (up 363.31% YoY), and the FY2025 full-year result was -$14.2 million, down 10094.24% from the prior year.
  • Cash from Financing Activities fell to $13.5 million in Q2 2026 per SCYX's latest filing, from $24.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $42.1 million in Q2 2022 and bottomed at -$36.6 million in Q2 2023.
  • Historically, Cash from Financing Activities has averaged $2.3 million across 5 years, with a median of $22000.0 in 2023.
  • The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 9569.01% in 2022, then sank 93793.33% in 2025.
  • Over 5 years, Cash from Financing Activities stood at -$183000.0 in 2022, then rose by 26.23% to -$135000.0 in 2023, then fell by 14.81% to -$155000.0 in 2024, then gained by 25.81% to -$115000.0 in 2025, then jumped by 11803.48% to $13.5 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $13.5 million, $24.0 million, and -$115000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -181.51 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 13.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.46 Mn
Mar 31, 2026 24.04 Mn
Dec 31, 2025 -115,000.00
Sep 30, 2025 29,000.00
Mar 31, 2025 -14.08 Mn
Dec 31, 2024 -155,000.00
Sep 30, 2024 31,000.00
Mar 31, 2024 -15,000.00
Dec 31, 2023 -135,000.00
Sep 30, 2023 34,000.00
Jun 30, 2023 -36.64 Mn
Mar 31, 2023 22,000.00
Sep 30, 2022 -183,000.00
Jun 30, 2022 42.06 Mn
Mar 31, 2022 6.72 Mn
Dec 31, 2021 30.48 Mn
Sep 30, 2021 4.53 Mn
Jun 30, 2021 32.18 Mn
Mar 31, 2021 -71,000.00
Dec 31, 2020 80.12 Mn